Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 3/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5143519 | 0.78 | CYP1A2 (0.42) | CYP1A2CYP2A6NR4A2TSHRLMNA | |
| SCHEMBL293462 | 0.78 | CYP1A2 (0.42) | CYP1A2CYP2A6NR4A2TSHRLMNA | |
| SCHEMBL29120011 | 0.74 | CYP1A2 (0.38) | CYP1A2CYP2A6NR4A2ALDH1A1 | |
| SCHEMBL3071001 | 0.73 | CYP2A6 (0.40) | CYP1A2CYP2A6TSHRLMNAMEN1 | |
| SCHEMBL6436724 | 0.68 | HPRT1 (0.50) | CYP1A2CYP2A6TSHRLMNAALDH1A1 | |
| SCHEMBL22749378 | 0.68 | CYP1A2 (0.35) | CYP1A2CYP2A6TSHRLMNAMEN1 | |
| SCHEMBL638983 | 0.68 | CYP1A2 (0.52) | CYP1A2CYP2A6NR4A2TSHRLMNA | |
| SCHEMBL9479816 | 0.65 | CYP1A2 (0.42) | CYP1A2CYP2A6NR4A2TSHRLMNA | |
| SCHEMBL2468811 | 0.65 | CYP1A2 (1.00) | CYP1A2CYP2A6NR4A2TSHRLMNA | |
| SCHEMBL29629127 | 0.65 | CYP1A2 (1.00) | CYP1A2CYP2A6NR4A2TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1285914-B1 | Nr1h4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1423370-A4 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1423111-A4 | FXR NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| EP-1423113-A4 | NR1H4 NUCLEAR RECEPTOR BINDING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2007-04-18 | — | — | EP | disclosed |
| US-20070010562-A1 | Nr1h4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2007-01-11 | — | — | US | disclosed |
| US-7098336-B2 | FXR NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2006-08-29 | — | — | US | disclosed |
| US-20060148876-A1 | Nr3b1 nuclear receptor binding 3-substituted pyrazoles | PHENEX PHARMACEUTICALS AG (DE) | 2006-07-06 | — | — | US | disclosed |
| EP-1536799-B1 | NOVEL 2-AMINO-4-OXOQUINAZOLONES AS LXR NUCLEAR RECEPTOR BINDING COMPOUNDS WITH PARTIAL AGONISTIC PROPERTIES | PHENEX PHARMACEUTICALS AG (DE) | 2006-05-10 | — | — | EP | disclosed |
| US-7034046-B2 | NR1H4 nuclear receptor binding compounds | PHENEX PHARMACEUTICALS AG (DE) | 2006-04-25 | — | — | US | disclosed |
| WO-2006002022-A2 | COMPOSITIONS AND METHODS USEFUL FOR THE TREATMENT OF HYPERGLYCEMIA | IMMUSOL INCORPORATED (US) | 2006-01-05 | — | — | WO | disclosed |
| EP-0923734-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | Trega Biosciences, Inc. (US) | 1999-06-23 | — | — | EP | disclosed |
| US-5874443-A | BIOSYNTHESIS | TREGA BIOSCIENCES, INC. (US) | 1999-02-23 | — | — | US | disclosed |
| CN-1202888-A | Isoquinoline derivatives and isoquinoline combinatorial libraries | TORREY PINES INST (US) | 1998-12-23 | — | — | CN | disclosed |
| US-5840500-A | OPIOD RECEPTORS AS ANALGESICS AND CENTRALLY ACTING PAIN KILLERS | TREGA BIOSCIENCES, INC. (US) | 1998-11-24 | — | — | US | disclosed |
| EP-0863877-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1998-09-16 | — | — | EP | disclosed |
| WO-1998034115-A1 | 4-SUBSTITUTED-QUINOLINE DERIVATIVES AND 4-SUBSTITUTE-QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998034111-A1 | TRICYCLIC TETRAHYDROQUINOLINE DERIVATIVES AND TRICYCLIC TETRAHYDROQUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-08-06 | — | — | WO | disclosed |
| WO-1998002741-A9 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998002741-A1 | QUINOLINE DERIVATIVES AND QUINOLINE COMBINATORIAL LIBRARIES | TREGA BIOSCIENCES, INC. (US) | 1998-01-22 | — | — | WO | disclosed |
| WO-1997016428-A1 | ISOQUINOLINE DERIVATIVES AND ISOQUINOLINE COMBINATORIAL LIBRARIES | TORREY PINES INSTITUTE FOR MOLECULAR STUDIES (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010562-A1 | Nr1h4 nuclear receptor binding compounds | NR1H4, NR1H2, NR1H3 | CYP1A2 421/4885CYP2A6 426/4885NR4A2 15/4885 |
| US-20060148876-A1 | Nr3b1 nuclear receptor binding 3-substituted pyrazoles | NR0B1, NR0B2, NR4A3 | CYP1A2 560/4885CYP2A6 970/4885NR4A2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.